Together, these results suggest that PRDX2 upregulation correlates with SOX11 overexpression and associates with worse outcome of the patients, suggesting that PRDX2 could be involved in MCL pathogenesis. This evidence concerns the gene PRDX2 and mantle cell lymphoma.